Cargando…

Level of Adherence to Prophylactic Osteoporosis Medication amongst Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: A Cross-Sectional Study

Objective. To estimate level of adherence to oral calcium and vitamin D supplementation as well as bisphosphonate amongst patients with PMR and GCA treated with glucocorticoids. Method. A total of 138 patients with the diagnosis of PMR and/or GCA registered in our department in December 2013. In thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Emamifar, A., Gildberg-Mortensen, Rannveig, Andreas Just, S., Lomborg, N., Asmussen Andreasen, R., Jensen Hansen, I. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603323/
https://www.ncbi.nlm.nih.gov/pubmed/26491449
http://dx.doi.org/10.1155/2015/783709
_version_ 1782394895881732096
author Emamifar, A.
Gildberg-Mortensen, Rannveig
Andreas Just, S.
Lomborg, N.
Asmussen Andreasen, R.
Jensen Hansen, I. M.
author_facet Emamifar, A.
Gildberg-Mortensen, Rannveig
Andreas Just, S.
Lomborg, N.
Asmussen Andreasen, R.
Jensen Hansen, I. M.
author_sort Emamifar, A.
collection PubMed
description Objective. To estimate level of adherence to oral calcium and vitamin D supplementation as well as bisphosphonate amongst patients with PMR and GCA treated with glucocorticoids. Method. A total of 138 patients with the diagnosis of PMR and/or GCA registered in our department in December 2013. In this cross-sectional study we interviewed all the patients to measure level of adherence to calcium and vitamin D, as well as bisphosphonates. Results. Out of the 118 included patients, 88.9% of them were adherent to their prescription. Only 2 patients (1.7%) did not take calcium and vitamin D at all and 10 patients (8.5%) took their medication infrequently, 9 and 1 out of 10 patients took the medication 50–100% of the time and less than 50% of the prescribed dose, respectively. Sixty-one patients received additional treatment with bisphosphonate and 96.6% were adherent to this therapy. The remaining 3.4% of the patients did not take the medication at all. Forgetfulness, adverse side effects, and lack of understanding of treatment benefits were the most significant causes for nonadherence to calcium and vitamin D. Conclusions. Contrary to what we expected this study found that adherence to osteoporosis preventive medication in patients with PMR and GCA was high.
format Online
Article
Text
id pubmed-4603323
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-46033232015-10-21 Level of Adherence to Prophylactic Osteoporosis Medication amongst Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: A Cross-Sectional Study Emamifar, A. Gildberg-Mortensen, Rannveig Andreas Just, S. Lomborg, N. Asmussen Andreasen, R. Jensen Hansen, I. M. Int J Rheumatol Research Article Objective. To estimate level of adherence to oral calcium and vitamin D supplementation as well as bisphosphonate amongst patients with PMR and GCA treated with glucocorticoids. Method. A total of 138 patients with the diagnosis of PMR and/or GCA registered in our department in December 2013. In this cross-sectional study we interviewed all the patients to measure level of adherence to calcium and vitamin D, as well as bisphosphonates. Results. Out of the 118 included patients, 88.9% of them were adherent to their prescription. Only 2 patients (1.7%) did not take calcium and vitamin D at all and 10 patients (8.5%) took their medication infrequently, 9 and 1 out of 10 patients took the medication 50–100% of the time and less than 50% of the prescribed dose, respectively. Sixty-one patients received additional treatment with bisphosphonate and 96.6% were adherent to this therapy. The remaining 3.4% of the patients did not take the medication at all. Forgetfulness, adverse side effects, and lack of understanding of treatment benefits were the most significant causes for nonadherence to calcium and vitamin D. Conclusions. Contrary to what we expected this study found that adherence to osteoporosis preventive medication in patients with PMR and GCA was high. Hindawi Publishing Corporation 2015 2015-09-29 /pmc/articles/PMC4603323/ /pubmed/26491449 http://dx.doi.org/10.1155/2015/783709 Text en Copyright © 2015 A. Emamifar et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Emamifar, A.
Gildberg-Mortensen, Rannveig
Andreas Just, S.
Lomborg, N.
Asmussen Andreasen, R.
Jensen Hansen, I. M.
Level of Adherence to Prophylactic Osteoporosis Medication amongst Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: A Cross-Sectional Study
title Level of Adherence to Prophylactic Osteoporosis Medication amongst Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: A Cross-Sectional Study
title_full Level of Adherence to Prophylactic Osteoporosis Medication amongst Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: A Cross-Sectional Study
title_fullStr Level of Adherence to Prophylactic Osteoporosis Medication amongst Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: A Cross-Sectional Study
title_full_unstemmed Level of Adherence to Prophylactic Osteoporosis Medication amongst Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: A Cross-Sectional Study
title_short Level of Adherence to Prophylactic Osteoporosis Medication amongst Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: A Cross-Sectional Study
title_sort level of adherence to prophylactic osteoporosis medication amongst patients with polymyalgia rheumatica and giant cell arteritis: a cross-sectional study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603323/
https://www.ncbi.nlm.nih.gov/pubmed/26491449
http://dx.doi.org/10.1155/2015/783709
work_keys_str_mv AT emamifara levelofadherencetoprophylacticosteoporosismedicationamongstpatientswithpolymyalgiarheumaticaandgiantcellarteritisacrosssectionalstudy
AT gildbergmortensenrannveig levelofadherencetoprophylacticosteoporosismedicationamongstpatientswithpolymyalgiarheumaticaandgiantcellarteritisacrosssectionalstudy
AT andreasjusts levelofadherencetoprophylacticosteoporosismedicationamongstpatientswithpolymyalgiarheumaticaandgiantcellarteritisacrosssectionalstudy
AT lomborgn levelofadherencetoprophylacticosteoporosismedicationamongstpatientswithpolymyalgiarheumaticaandgiantcellarteritisacrosssectionalstudy
AT asmussenandreasenr levelofadherencetoprophylacticosteoporosismedicationamongstpatientswithpolymyalgiarheumaticaandgiantcellarteritisacrosssectionalstudy
AT jensenhansenim levelofadherencetoprophylacticosteoporosismedicationamongstpatientswithpolymyalgiarheumaticaandgiantcellarteritisacrosssectionalstudy